2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Adverse Events, Biological Processes, Apoptosis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3550 Epcoritamab plus lenalidomide and rituximab (E+R2) shows a consistent safety profile and efficacy benefit over R2 in patients with relapsed or refractory follicular lymphoma (R/R FL): Updated subgroup analyses from the randomized phase 3 EPCORE FL-1 trial

Lorenzo Falchi, MD, Rong Tao, MD,PhD2, Marcel Nijland, MD, PhD3, Kim M. Linton Sr, MBChB, MD4, Mark Fesler, MD5, Panagiotis Tsirigotis, MD, PhD6, Juliana Pereira Sr, MD, PhD7, Sonia González De Villambrosia8, Loïc Ysebaert, PhD9, Vinay Vanguru, MBBS10, Su-Peng Yeh, MD11, Umberto Vitolo, MD12, Takayuki Ikezoe, MD, PhD13, Ashley Freeman, MD14, Vanja Zeremski, MD15, Zsolt Nagy16, Irit Avivi Mazza, MD17, Koji Izutsu, MD, PhD18, Michal Kwiatek, MD, PhD19, Catherine Thieblemont, MD, PhD20, Gauri Sunkersett21, Rastislav Moskal, PharmD22, Nabanita Mukherjee, PhD23, Yukun Li24, Neha Dixit, PhD25, Brian Elliott, MD26, Franck Morschhauser, phd27
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Fudan University Shanghai Cancer Hospital, Shanghai, China
3 University Medical Center Groningen, University of Groningen, Groningen, Netherlands
4 The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
5 St. Luke's Hospital, Chesterfield, Missouri, United States
6 Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
7 Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP) and Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil
8 Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain
9 Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France
10 Faculty of Medicine and Health, University of Sydney, Sydney, Australia, Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia
11 China Medical University, Taichung, Taiwan
12 INOC-Istituto Nazionale Oncologico Candiolo; IRCCS, Candiolo (Turin), Turin, Italy
13 Fukushima Medical University, Fukushima, Japan
14 BC Cancer, Victoria, Canada
15 Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany
16 The Semmelweis University, Budapest, Hungary
17 Tel Aviv Sourasky Medical Centre, Tel Aviv University, Tel Aviv, Israel
18 National Cancer Center Hospital, Tokyo, Japan
19 Aidport Clinical Trials Hospital, Skorzewo (Poznan), Poland
20 Hôpital Saint-Louis, Paris, France
21 AbbVie Inc., North Chicago, United States
22 AbbVie, Prague, Czech Republic
23 AbbVie Inc., North Chicago, United States
24 AbbVie Inc., North Chicago, United States
25 AbbVie Inc., North Chicago, United States
26 Genmab, Plainsboro, United States
27 Hôpital Claude Huriez, Lille, France

Background

While the treatment landscape for R/R FL continues to evolve, the need remains for options that can provide better clinical outcomes across a broad patient (pt) population. Epcoritamab, a subcutaneous CD3×CD20 bispecific antibody, is approved globally as fixed-duration therapy with R2 (E+R2) in 2L+ FL based on the phase 3 EPCORE FL-1 trial (NCT05409066). With a median follow-up of 14.8 mo, E+R2 showed superiority over R2 in the dual primary endpoints of overall response rate (ORR; 95% [95% CI, 92–97] and 79% [74–84], respectively; P<.0001) and progression-free survival (PFS; HR, 0.21 [95% CI: 0.14–0.31]; P<.0001) (Falchi Lancet 2026). Subgroup analyses may inform treatment decisions based on pt characteristics; here we report efficacy and safety in an expanded set of clinically relevant subgroups from the EPCORE FL-1 trial. Longer follow-up (~2 years) for the overall trial population and subgroups is expected at the time of the congress including PFS, OS, TTNT, and the first reporting of MRD, reinforcing the deep and durable responses previously demonstrated in response to E+R2.

Methods

The design of this trial and analyses were previously described (Falchi 2026); briefly, pts ≥18 y old with CD20+ R/R FL and ECOG 0–2 who had received ≥1 prior therapy were randomized to E+R2 or R2 for up to 12 cycles. Subgroups assessed included baseline renal function (normal [CrCl ≥90 mL/min], mild to moderate impairment [CrCl 30–89 mL/min]), bone marrow involvement (BM; yes, no), presence of extranodal disease (EN; yes, no), lactate dehydrogenase level (LDH; normal [≤280 U/L], high [>280 U/L]), and SUVmax (high [>13], low [≤13]).

Results

As of 24 May 2025, 488 pts were enrolled (E+R², n=243; R², n=245); 243 and 238, respectively, received ≥1 dose of study drug. Median duration of epcoritamab was 10.4 mo.

Consistent with overall results, ORR favored E+R2 vs R2 for all subgroups assessed including renal function subgroups (normal: 97.6% [121/124 pts] vs 77.1% [101/131 pts]; impaired: 92.4% [110/119 pts] vs 81.6% [93/114 pts]), and subgroups associated with tumor burden and disease severity (BM [yes, 92.8% {64/69 pts} vs 70.1% {47/67 pts}; no, 95.7% {156/163 pts} vs 84.0% {142/169 pts}], EN [yes, 94.1% {95/101 pts} vs 76.2% {80/105 pts}; no, 95.8% {136/142 pts} vs 81.4% {114/140 pts}], LDH [high, 91.9% {79/86 pts} vs 66.2% {49/74 pts}; normal, 96.8% {149/154 pts} vs 84.7% {138/163 pts}], SUVmax [high, 94.5% {86/91 pts} vs 79.0% {83/105 pts}; low, 95.2% {139/146 pts} vs 81.7% {103/126 pts}]).

Similarly, complete response rates (CRR) favored E+R2 vs R2 for all subgroups assessed including renal function subgroups (normal: 87.1% [108/124 pts] vs 50.4% [66/131 pts]; impaired: 78.2% [93/119 pts] vs 49.1% [56/114 pts]), BM (yes, 71.0% [49/69 pts] vs 40.3% [27/67 pts]; no, 89.6% [146/163 pts] vs 55.6% [94/169 pts]), EN (yes, 81.2% [82/101 pts] vs 45.7% [48/105 pts]; no, 83.8% [119/142 pts] vs 52.9% [74/140 pts]), LDH (high, 72.1% [62/86 pts] vs 39.2% [29/74 pts]; normal, 88.3% [136/154 pts] vs 55.8% [91/163 pts]), and SUVmax (high, 81.3% [74/91 pts] vs 46.7% [49/105 pts]; low, 82.9% [121/146 pts] vs 54.8% [69/126 pts]).

PFS HRs also favored E+R2 vs R2 for all subgroups including renal function (normal: 0.20 [95% CI, 0.12–0.34], events/pts: 18/124 and 60/131; impaired: 0.24 [0.14–0.42], 17/119 and 46/114), BM (yes, 0.31 [95% CI, 0.16–0.59], 13/69 and 29/67; no, 0.16 [0.09–0.27], 18/163 and 73/169), EN (yes, 0.25 [0.14–0.45], 16/101 and 43/105; no, 0.19 [0.11–0.32], 19/142 and 63/140), LDH (high, 0.30 [95% CI, 0.18–0.51], 21/86 and 40/74; normal, 0.15 [0.08–0.26], 14/154 and 63/163), and SUVmax (high, 0.20 [0.11–0.37], 13/91 and 51/105; low, 0.25 [0.15–0.42], 22/146 and 49/126).

The E+R2 safety profile was manageable across all subgroups and was generally consistent with the overall trial population.

Conclusion

Consistent with the overall EPCORE FL-1 population, clinically meaningful improvements were observed with E+R2 over R2 across all subgroups assessed, including in pts with impaired renal function and higher tumor burden. This is consistent with previously presented subgroups of age, comorbidity burden, LOT, FLIPI, and POD24, supporting E+R2 as an option across a wide range of R2-eligible pts. Safety findings were also consistent with the overall population. Collectively, the findings from EPCORE FL-1 continue to support fixed-duration E+R2 as a new benchmark 2L+ standard of care for a broad population of pts with R/R FL.

Lorenzo Falchi, MD: Genmab - Honoraria; Kite - Honoraria; AbbVie - Honoraria; Roche - Honoraria; AbbVie - Research Funding; Roche - Research Funding; Innate Pharma - Research Funding; Genentech - Research Funding; AstraZeneca - Research Funding; BeOne Medicines - Research Funding; Genmab - Research Funding; Genmab - Consultancy (Includes expert testimony); Seagen - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Evolveimmune - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Chugai - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony)